Search hospitals

>

California

>

Stanford

Stanford University

Claim this profile

Stanford, California 94305

Global Leader in Type 1 Diabetes

Global Leader in Diabetes

Conducts research for Depression

Conducts research for Cancer

Conducts research for Premature Birth

1398 reported clinical trials

207 medical researchers

Photo of Stanford University in StanfordPhoto of Stanford University in StanfordPhoto of Stanford University in Stanford

Summary

Stanford University is a medical facility located in Stanford, California. This center is recognized for care of Type 1 Diabetes, Diabetes, Depression, Cancer, Premature Birth and other specialties. Stanford University is involved with conducting 1,398 clinical trials across 1,707 conditions. There are 207 research doctors associated with this hospital, such as Andrei Iagaru, MD, Robert Lowsky, MD, Christopher Chen, and Antonio Hardan, MD.

Area of expertise

1

Type 1 Diabetes

Global Leader

Stanford University has run 100 trials for Type 1 Diabetes. Some of their research focus areas include:

mIAA positive
IA-2A positive
ICA positive
2

Diabetes

Global Leader

Stanford University has run 76 trials for Diabetes. Some of their research focus areas include:

GAD65A positive
mIAA positive
IA-2A positive

Top PIs

Clinical Trials running at Stanford University

Ovarian Cancer

Cancer

Lazy Eye

Atrial Fibrillation

Carcinoid Tumor

Depression

Fallopian Tube Cancer

Prostate Cancer

Neuroendocrine Tumors

Urinary Incontinence

Image of trial facility.

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).

Recruiting

2 awards

Phase 3

Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Image of trial facility.

B7-H3 CAR T Cells

for Ovarian Cancer

This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

Recruiting

1 award

Phase 1

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Stanford University?

Where is Stanford University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Stanford University accept?

What awards or recognition has Stanford University received?